Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Starowicz, S. Nigam, V. Marzo (2007)
Biochemistry and pharmacology of endovanilloids.Pharmacology & therapeutics, 114 1
L. Mestre, F. Correa, A. Arévalo-Martı́n, E. Molina-Holgado, M. Valenti, G. Ortar, V. Marzo, C. Guaza (2005)
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosisJournal of Neurochemistry, 92
V. Haller, D. Cichewicz, S. Welch (2006)
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.European journal of pharmacology, 546 1-3
AG, 2-arachidonoylglycerol
A. Brown (2007)
Novel cannabinoid receptorsBritish Journal of Pharmacology, 152
K. Maresz, E. Carrier, E. Ponomarev, C. Hillard, B. Dittel (2005)
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuliJournal of Neurochemistry, 95
K. Tsuboi, Yong-xin Sun, Y. Okamoto, N. Araki, T. Tonai, N. Ueda (2005)
Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase*Journal of Biological Chemistry, 280
D. Lambert, Di Marzo (1999)
The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic?Current medicinal chemistry, 6 8
HPLC, high-pressure liquid chromatography
D. Ure, Moses Rodriguez (2000)
Extensive Injury of Descending Neurons Demonstrated by Retrograde Labeling in a Virus‐Induced Murine Model of Chronic Inflammatory DemyelinationJNEN: Journal of Neuropathology & Experimental Neurology, 59
D. Amantea, P. Spagnuolo, M. Bari, F. Fezza, C. Mazzei, C. Tassorelli, L. Morrone, M. Corasaniti, M. Maccarrone, G. Bagetta (2007)
Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17β‐estradiolThe FEBS Journal, 274
T. Bisogno, V. Marzo (2007)
Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders.Pharmacological research, 56 5
Di Marzo (2001)
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cellsBiochem. J., 358
T. Genovese, E. Esposito, E. Mazzon, R. Paola, R. Meli, P. Bramanti, D. Piomelli, A. Calignano, S. Cuzzocrea (2008)
Effects of Palmitoylethanolamide on Signaling Pathways Implicated in the Development of Spinal Cord InjuryJournal of Pharmacology and Experimental Therapeutics, 326
F. Docagne, Vilma Muñetón, D. Clemente, C. Ali, F. Loria, F. Correa, M. Hernangómez, L. Mestre, D. Vivien, C. Guaza (2007)
Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activationMolecular and Cellular Neuroscience, 34
tumour necrosis factor; TRP, transient receptor potential
A. Sheerin, Xia Zhang, Deborah Saucier, M. Corcoran (2004)
Selective Antiepileptic Effects of N‐Palmitoylethanolamide, a Putative EndocannabinoidEpilepsia, 45
D. Filippis, A. D’Amico, M. Cinelli, G. Esposito, V. Marzo, T. Iuvone (2008)
Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in ratsJournal of Cellular and Molecular Medicine, 13
J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado, R. Mechoulam, C. Benito, J. Romero, Augusto Silva, M. Guzmán, S. Nataf, I. Galve-Roperh (2008)
The CB2 Cannabinoid Receptor Controls Myeloid Progenitor TraffickingJournal of Biological Chemistry, 283
M. Heneka, G. Landreth, M. Hüll (2007)
Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disordersNature Clinical Practice Neurology, 3
Y. Yiangou, P. Facer, P. Durrenberger, I. Chessell, A. Naylor, C. Bountra, Richard Banati, Praveen Anand (2006)
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cordBMC Neurology, 6
A. Cabranes, K. Venderová, E. Lago, F. Fezza, Antonio Sánchez, L. Mestre, M. Valenti, A. García‐Merino, J. Ramos, V. Marzo, J. Fernández-Ruiz (2005)
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosisNeurobiology of Disease, 20
D. Baker, G. Pryce, J. Croxford, Peter Brown, R. Pertwee, J. Huffman, L. Layward (2000)
Cannabinoids control spasticity and tremor in a multiple sclerosis modelNature, 404
(2007)
Intestinal monoacylglycerol metabolism: developmental and nutritional regulation of monoacylglycerol lipase and monoacylglycerol acyltransferase
Anke Witting, Lanfen Chen, E. Cudaback, A. Straiker, L. Walter, B. Rickman, T. Möller, C. Brosnan, N. Stella (2006)
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection.Proceedings of the National Academy of Sciences of the United States of America, 103 16
C. Benito, J. Romero, R. Tolón, D. Clemente, F. Docagne, C. Hillard, C. Guaza, J. Romero (2007)
Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple SclerosisThe Journal of Neuroscience, 27
S. Skaper, A. Buriani, R. Toso, L. Petrelli, S. Romanello, L. Facci, A. Leon (1996)
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.Proceedings of the National Academy of Sciences of the United States of America, 93 9
L. Petrocellis, P. Marini, I. Matias, A. Moriello, K. Starowicz, L. Cristino, S. Nigam, V. Marzo (2007)
Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells.Experimental cell research, 313 14
R. Cunard, Dennis DiCampli, D. Archer, Jennifer Stevenson, M. Ricote, C. Glass, C. Kelly (2002)
WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo.Journal of immunology, 169 12
FCS, foetal calf serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase
S. Petrosino, E. Palazzo, V. Novellis, T. Bisogno, F. Rossi, S. Maione, V. Marzo (2007)
Changes in spinal and supraspinal endocannabinoid levels in neuropathic ratsNeuropharmacology, 52
6¢-carboxy-tetramethyl rhodamine; TGF, tumour growth factor
G. Muccioli, N. Stella (2008)
Microglia produce and hydrolyze palmitoylethanolamideNeuropharmacology, 54
David Baker, G. Pryce, J. Croxford, Peter Brown, R. Pertwee, Alexandros Makriyannis, Atmaram Khanolkar, Lorna Layward, F. Fezza, T. Bisogno, V. Marzo (2001)
Endocannabinoids control spasticity in a multiple sclerosis modelThe FASEB Journal, 15
Niki Tsakiri, I. Kimber, N. Rothwell, E. Pinteaux (2008)
Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokine synthesis in neuronesMolecular and Cellular Neuroscience, 38
D. Centonze, S. Rossi, A. Finazzi-Agrò, G. Bernardi, M. Maccarrone (2007)
The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.International review of neurobiology, 82
Ikuo Tsunoda, L. Kuang, J. Libbey, R. Fujinami (2003)
Axonal injury heralds virus-induced demyelination.The American journal of pathology, 162 4
J. Palazuelos, N. Davoust, B. Julien, E. Hatterer, T. Aguado, R. Mechoulam, C. Benito, J. Romero, Augusto Silva, M. Guzmán, S. Nataf, I. Galve-Roperh (2008)
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.The Journal of biological chemistry, 283 19
A. Franklin, S. Parmentier-Batteur, L. Walter, D. Greenberg, N. Stella (2003)
Palmitoylethanolamide Increases after Focal Cerebral Ischemia and Potentiates Microglial Cell MotilityThe Journal of Neuroscience, 23
P. Pais, E. Moyano, L. Puignou, M. Galceran (1997)
Liquid chromatography-atmospheric-pressure chemical ionization mass spectrometry as a routine method for the analysis of mutagenic amines in beef extracts.Journal of chromatography. A, 778 1-2
V. Marzo, D. Melck, P. Orlando, T. Bisogno, Orna Zagoory, M. Bifulco, Zvi Vogel, L. Petrocellis (2001)
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.The Biochemical journal, 358 Pt 1
S. O’Sullivan (2007)
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptorsBritish Journal of Pharmacology, 152
R. Cunard, Dennis DiCampli, D. Archer, Jennifer Stevenson, M. Ricote, C. Glass, C. Kelly (2002)
WY14,643, a PPARα Ligand, Has Profound Effects on Immune Responses In Vivo1The Journal of Immunology, 169
A. Pachner, Jennifer Brady, K. Narayan (2007)
Antibody-secreting cells in the central nervous system in an animal model of MS: Phenotype, association with disability, and in vitro production of antibodyJournal of Neuroimmunology, 190
J. Loverme, G. Rana, R. Russo, A. Calignano, D. Piomelli (2005)
The search for the palmitoylethanolamide receptor.Life sciences, 77 14
V. Marzo, S. Goparaju, Lei Wang, Jie Liu, S. Batkai, Z. Járai, F. Fezza, G. Miura, R. Palmiter, T. Sugiura, G. Kunos (2001)
Leptin-regulated endocannabinoids are involved in maintaining food intakeNature, 410
D. Amantea, P. Spagnuolo, M. Bari, F. Fezza, C. Mazzei, C. Tassorelli, L. Morrone, M. Corasaniti, M. Maccarrone, G. Bagetta (2007)
Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol.The FEBS journal, 274 17
T. Bisogno, A. Martire, S. Petrosino, P. Popoli, V. Marzo (2008)
Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's diseaseNeurochemistry International, 52
M. Heneka, G. Landreth, M. Hüll (2007)
Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.Nature clinical practice. Neurology, 3 9
S. Ortega‐Gutiérrez, E. Molina-Holgado, A. Arévalo-Martı́n, F. Correa, A. Viso, M. López-Rodríguez, V. Marzo, C. Guaza (2005)
Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosisThe FASEB Journal, 19
Alberto Lledó, J. Borrell, Carmen Guaza (1999)
Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination.European journal of pharmacology, 372 1
Cannabinoids have recently been approved as a treatment for pain in multiple sclerosis (MS). Increasing evidence from animal studies suggests that this class of compounds could also prove efficient to fight neurodegeneration, demyelination, inflammation and autoimmune processes occurring in this pathology. However, the use of cannabinoids is limited by their psychoactive effects. In this context, potentiation of the endogenous cannabinoid signalling could represent a substitute to the use of exogenously administrated cannabinoid ligands. Here, we studied the expression of different elements of the endocannabinoid system in a chronic model of MS in mice. We first studied the expression of the two cannabinoid receptors, CB1 and CB2, as well as the putative intracellular cannabinoid receptor peroxisome proliferator‐activated receptor‐α. We observed an upregulation of CB2, correlated to the production of proinflammatory cytokines, at 60 days after the onset of the MS model. At this time, the levels of the endocannabinoid, 2‐arachidonoylglycerol, and of the anti‐inflammatory anandamide congener, palmithoylethanolamide, were enhanced, without changes in the levels of anandamide. These changes were not due to differences in the expression of the degradation enzymes, fatty acid amide hydrolase and monoacylglycerol lipase, or of biosynthetic enzymes, diacylglycerol lipase‐α and N‐acylphosphatidylethanolamine phospholipase‐D at this time (60 days). Finally, the exogenous administration of palmitoylethanolamide resulted in a reduction of motor disability in the animals subjected to this model of MS, accompanied by an anti‐inflammatory effect. This study overall highlights the potential therapeutic effects of endocannabinoids in MS.
European Journal of Neuroscience – Wiley
Published: Aug 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.